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The impact of molecular biology on
clinical neurology
Advances in molecular biology have increased our understanding of
both inherited and sporadic forms of neurological disease. In this review,
the impact of these advances is discussed in relation to specific neuro-
logical conditions. These include the hereditary neuropathies and ataxias,
Huntington’s disease, and the muscular dystrophies, as well as Alzheim-
er’s disease, Parkinson’s disease, and motor neuron disease. Genetic
channelopathies, such as familial hemiplegic migraine, are also described.
Although knowledge in this area overall is still relatively scant, current
advances in molecular biology have helped in the reclassification of some
neurological disorders, thereby providing a further step towards the
development of rational therapies to treat these conditions.
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Introduction
The 1990s have been described as the ‘decade of the brain’, to reflect
the fact that major achievements in various aspects of neuroscience,
in particular molecular biology, were made during that decade. These ad-
vances have increased our understanding of the basic pathophysiological
mechanisms from which neurological disorders develop. In addition to
providing insights into inherited conditions, molecular biology has insti-
gated entirely new approaches to the many ‘sporadic’ neurological
diseases. Practice and treatment in clinical neurology is still largely based
on phenotypic features—that is, symptoms and signs—although this
trend is set to change. Increased understanding of the pathophysiological
mechanisms that underlie neurological disorders will allow for a more
rationalised approach to their diagnosis, classification, and, perhaps,
subsequent therapy. A complete account of the molecular advances in
neuroscience is beyond the scope of this article. Instead, this review
will discuss specific neurological disorders and illustrate the impact of
molecular biology on their management in clinical practice.
Hereditary neuropathies
Charcot-Marie-Tooth (CMT) disease or hereditary motor and sensory neuro-
pathy (HMSN) is conventionally diagnosed and classified by clinical
HKMJ Vol 7 No 1 March 2001      41
Molecular biology and clinical neurology
features, mode of inheritance, electrophysiological
findings, and, in selected cases, histopathology. Heredi-
tary motor and sensory neuropathy I and II are mostly
autosomal dominant conditions. Hereditary motor and
sensory neuropathy I is a generalised demyelinating
neuropathy, whereas HMSN II is an axonal degenera-
tive neuropathy. Hereditary motor and sensory neuro-
pathy III, or Dejerine-Sottas disease (DSD), is a rare
autosomal recessive hypodemyelinating neuropathy of
early onset, which results in severe disability during
childhood. Other non-DSD autosomal recessive HMSNs
also cause severe neuropathies. Hereditary motor and
sensory neuropathy X is of X-linked dominant inherit-
ance. It was thought to be a primary axonopathy with
secondary demyelination. Electrophysiological ab-
normalities may be intermediate and difficult to distin-
guish from those of HMSN I or II. Another autosomal
dominant disorder is hereditary neuropathy with liabil-
ity to pressure palsies (HNPP). Hereditory neuropathy
manifests as recurrent entrapment neuropathies and a
progressive generalised axonal neuropathy of variable
severity, and has typical histopathological findings.
Based on newer findings in molecular genetics, the
classification of HSMN has been revised (Table). He-
reditary motor and sensory neuropathy I is subdivided
into CMT 1A to 1C; HMSN II into CMT 2A to 2D,
HMSN III to DSD A, B, and autosomal dominant DSD,
and HMSN X to CMT X1 and X2. Charcot-Marie-Tooth
disease 4 specifically indicates autosomal recessive
inheritance other than DSD, and is subdivided into
CMT 4A to 4C and HMSN-Lom. The underlying
genetic defects and probable pathogenic mechanisms
of many myelinopathies are now known. Peripheral
myelin protein 22 (PMP22) and myelin protein zero
(P0) are components of peripheral nerve myelin. The
former is encoded by the PMP22 gene at chromosome
locus 17p11.2, and the latter by P0 gene at 1q22-q23.
Mutations of PMP22 are associated with CMT 1A,
HNPP, and DSD A.1-4 Mutations of P0 are found in
CMT 1B, DSD B, and congenital hypomyelination
neuropathy (CH).5-8 Some researchers now consider
CMT 1 and DSD to be a different spectrum of the same
disease. Mutations of the Cx32 gene at chromosome
locus Xq13.1, which encodes the gap-junction protein
connexin 32, are found in some CMT X1 cases. 9,10
Mutations of the EGR2 gene at 10q21-22, which encodes
a transcription factor that regulates gene expression,
are associated with CMT 1C, DSD, and CH.11,12 No
single gene has so far been associated with CMT 2
and 4, but some linkages have been reported—CMT 2A
to 1p35-36,13,14 2B to 3q13-22,15 2D to 7p14,16 4A to
8q12-21.117 or 5q23-q33,18 4B to 11q23.1,19 and
HMSN-Lom to 8q24.20 Unlike the myelinopathies,
the pathogenic implications of these linkages are still
not understood.
Hereditary motor and sensory neuropathies have no
specific treatment. For the purposes of genetic coun-
selling, diagnosis can be made in most cases by using
conventional techniques. Nevertheless, genetic testing
can be helpful in some of these disorders. The most
useful molecular test is perhaps the detection of Cx32-
related abnormalities in suspected HMSN X, because
electrodiagnostic parameters may overlap with those of
HMSN I or II. A negative result for a genetic test, however,
Table. Molecular basis for differentiation and diagnosis of some hereditary neuropathies
Disease Locus Gene Mutation
Myelinopathies
CMT 1A 17p11.2 PMP22 Duplications, point mutations
CMT 1B 1q22-23 P0 Point mutations, small deletions
CMT 1C 10q21-22 ERG2 Point mutations
CMT X1 Xq13.1 Cx32 Point mutations, small and large deletions, frameshift mutations
CMT X2 ? ?
HNPP 17p11.2 PMP22 Deletion, frameshift-nonsense mutations
DSD A 17p11.2 PMP22 Point mutations
DSD B 1q22-23 P0 Point mutations, small deletions, frameshift mutations
DSD AD 10q21-22 ERG2 Point mutations
8q23-24 ?
CH 1q22-23 P0 Point mutations
10q21-22 ERG2 Point mutations
CMT 4A 8q12-21.1 ?
5q23-33 ?
CMT 4B 11q23.1 ?
HMSN-Lom 8q24 ?
Axonal neuropathies
CMT 2A 1p35-36 ?
CMT 2B 13q13-22 ?
CMT 2C ? ?
CMT 2D 7p14 ?
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does not exclude the diagnosis. Detection of PMP22-
related abnormalities is helpful in the assessment of
families with HNPP. There may be considerable
phenotypic heterogeneity within the same family
such that conventional methods may not detect all
affected members. Nerve biopsy is invasive and
cannot be justified in asymptomatic cases.
Hereditary ataxias
Friedreich’s ataxia (FA) is the most common form of
hereditary ataxia in Caucasians and it is inherited as
an autosomal recessive condition. It manifests with
progressive gait and limb ataxia, areflexia, pyramidal
signs, optic atrophy, deafness, cardiomyopathy, and
an increased risk of diabetes mellitus. In the early
1980s, Harding21 revised the classification of heredi-
tary ataxias according to clinical features and mode of
inheritance, and proposed the diagnostic criteria for
FA. In 1996, the mutation in FA was identified as a
GAA trinucleotide expansion in the FRDA gene at
chromosome 9.22,23 The molecular definition of FA
based on GAA expansion mutation is broader than
the previous phenotype-based definition, because the
same deficit can be found in ataxic syndromes that are
not included in Harding’s criteria.24 There is a positive
correlation between the size of the GAA expansion
and the severity of the clinical disease. Small expan-
sions are associated with a later age of onset and
atypical clinical features. The FRDA gene encodes the
protein, frataxin. The function of frataxin is still not
fully understood, but evidence suggests that it may
be a mitochondrial protein.25 Deficiency in frataxin
is associated with mitochondrial iron accumulation
and cell death from oxidative stress. The expression
of frataxin is high in the heart and pancreas, and
relatively high in the spinal cord. Reduced frataxin
levels in these structures is the probable cause of
cardiomyopathy, diabetes mellitus, and neuronal loss.
A confident diagnosis of FA can usually be made
clinically. The main indication for genetic analysis
in FA is in diagnosing atypical cases.26 The role of
genetic counselling in FA appears limited. Firstly,
many couples would have completed their families
before the index case manifests, usually at the time of
puberty, such that the genetic confirmation is usually
too late to influence their decisions to have subsequent
offspring. Secondly, because the frequency of the het-
erozygous mutation in the general population is low
(1 in 85 among Caucasians), the chance of disease trans-
mission by healthy siblings to their offspring is esti-
mated to be less than 1 in 300, even if they are carriers.
Genetic screening in siblings of the index case is, thus
not generally recommended. As with HMSN, there is
currently no specific treatment available for FA.
Harding’s classification of the autosomal dominant
cerebellar ataxias (ADCA) was based on phenotypic
abnormalities. Autosomal dominant cerebellar ataxia
I is associated with ophthalmoplegia, optic atrophy,
dementia, or extrapyramidal features. Autosomal
dominant cerebellar ataxia II is characterised by pig-
mentary retinopathy. Autosomal dominant cerebellar
ataxia III presents with pure ataxia of late onset,
whereas ADCA IV—which includes additional fea-
tures of deafness or neuropathy—probably represents
a mitochondrial disorder. The genetic heterogeneity
underlying ADCA is now recognised. Autosomal
dominant cerebellar ataxias are subdivided into spinoc-
erebellar ataxia (SCA) types 1 to 8, although there is
considerable phenotypic overlap among them. Five
genotypes are associated with the CAG trinucleotide
repeat: SCA 1 with gene locus at 6p23,27 SCA 2 at
12q24,28 SCA 3 at 14q24.3-q31,29 SCA 6 at 19p13,30 and
ADCA II or SCA 7 at 3p12-21.1.31-33 Apart from SCA 6,
in which the gene locus encodes for the a 1A-subunit
of the P/Q-type voltage-gated calcium channel, loci of
the other SCA types encode their respective ataxins,
the functions of which are still unknown. Spinocere-
bellar ataxia 8 is associated with CTG expansion at
13q21.34 Autosomal dominant cerebellar ataxia III
has been renamed SCA 5 and its gene locus lies on
chromosome 11.35
At present, the pathogenic basis of these genotypic
abnormalities is still poorly understood, so that the
impact of this reclassification on patient management
is not significant. Occasionally, ADCA may present
with prominent extrapyramidal features that are par-
tially levodopa responsive. This presentation is more
common in patients with SCA 3, formerly known as
Machado-Joseph disease. This association might have
a therapeutic implication, although the decision to use
levodopa is based on clinical judgement.
Other trinucleotide repeat disorders
Apart from FA and SCA 1, 2, 3, 6, 7, and 8, other tri-
nucleotide repeat disorders include myotonic dystro-
phy (MyoD), Huntington’s disease, dentatorubropalli-
doluysian atrophy (DRPLA), X-linked spinobulbar
muscular atrophy, and fragile X syndromes. These tri-
nucleotide repeat disorders have their own distinctive
neurological features.
Myotonic dystrophy is the first disease to be rec-
ognised as showing anticipation—a phenomenon of
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increasing disease severity and earlier age of onset in
successive generations. The mutation underlying
MyoD is an unstable expansion of the CTG repeat in
the DMPK gene on chromosome 19,36-39 and anticipa-
tion is caused by transmission of an increased number
of trinucleotide repeats. The age of onset and clinical
features of MyoD correlate with the size of the tri-
nucleotide expansion. The size of the expansion can
also increase with time, which accounts for the mid-
life onset in classical MyoD and its progressive
course.40 Allelic mosaicism is present within an indivi-
dual, thus resulting in variable repeat sizes between
different organs and even among the same type of
somatic cells. Despite identification of the underlying
genetic defect, the pathogenic mechanism of MyoD is
still poorly understood.
Muscular dystrophies and the principles of
gene therapy
In the 1950s, Walton and his colleagues classified
muscular dystrophies into Duchenne muscular dystro-
phy (DMD), facioscapulohumeral dystrophy, and MyoD
according to their clinical patterns. A fourth type, limb
girdle muscular dystrophy (LGMD), was added to
include all dystrophies other than the three already
mentioned. By grouping different phenotypes into one
entity, the Walton classification system did not account
for the heterogeneity within LGMD. Subsequently,
immunohistochemical techniques have enabled mis-
classified conditions, such as metabolic myopathies,
mitochondrial myopathies, and various storage dis-
orders, to be distinguished from LGMD. Specific de-
ficiencies of membrane protein components, including
dystrophin and sarcoglycan, were also discovered.
Their identification enabled a histological classifica-
tion of some of the dystrophies into dystrophinopathy
and sarcoglycanopathy, the former including Duchenne
and Becker dystrophies, and the latter some of the
LGMDs.
Duchenne and Becker dystrophies are both X-linked
diseases. Existing evidence suggests that they are the
same disease entity at different ends of a continuous
spectrum. Patients with DMD become wheelchair-
dependent at about the age of 12 years, whereas those
with Becker dystrophy are ambulant beyond the age
of 15 years. There is an intermediate variant, denoted
‘outliers’, in which the ability to walk is retained after
the age of 12 years but not beyond 15 years. In DMD,
staining for dystrophin shows none or only a few
positive fibres. In Becker dystrophy, the deficiency is
partial or, more often, related to reduced amounts of
smaller molecular weight proteins. Cloning of the
dystrophin gene in 1987 enabled a new understanding
of the dystrophinopathies.41 A deletion of this gene
of variable size, encoding for dystrophin, is demon-
strated in most cases of DMD and Becker dystrophy.
Out-of-frame mutations, which create a translational
stop codon downstream from the distal breakpoint
and thereby disrupting the open reading frame, account
for the DMD phenotype. In contrast, the reading frame
is maintained in Becker dystrophy so that a semi-
functional, truncated protein can still be produced. The
reading frame explanation accounts for the phenotypic
variations seen in most cases.
A definite diagnosis of DMD can be based on the
clinical picture, gross elevation of serum creatine
kinase, and muscle biopsy findings. Dystrophin anti-
body for histological staining is commercially avail-
able. Since the dystrophin gene is very large (more
than 2000 kb of genomic DNA), it is prone to sponta-
neous mutations. Approximately one third of DMD
cases are sporadic. It is important to determine the
carrier status of the mother and female siblings in
isolated cases during genetic counselling. A genetic
diagnosis of DMD carrier status can be made in cases
of gene deletion or duplication.The mother of a
patient with sporadic DMD will still have a 14% risk
of having another affected child, despite a negative
DNA analysis, however.42 This is because of germline
mosaicism, in which the mother may harbour a muta-
tion in the oocytes but not in the tested leukocytes.
Thus, genetic tests cannot totally exclude carrier sta-
tus in the mother of a patient with sporadic DMD, and
female offspring should be investigated independently.
Genetic analysis has also refined the classification
of LGMD disorders. The prevalence of LGMD is ap-
proximately 1 in 100 000. Most LGMD phenotypes
demonstrate weakness in a limb-girdle distribution,
with sparing of the facial, extra-ocular, and pharyngeal
mus-cles. The onset is usually around puberty. A geno-
type-phenotype correlation can be difficult because the
onset and progress are variable even with the same
mutation. About 10% of LGMD disorders are auto-
somal dominant (type 1), with 1A linked to 5q,43 1B
to 1q11-21, 44 and 1C to the CAV3 gene at 3p25, which
encodes caveolin-3.45 For autosomal recessive LGMD
(type 2) disorders, 2A is linked to the CAPN3 gene
at 15q15, encoding for calpain-3, 46-48 2B to the FER-1
gene at 2p13 for dysferlin,49,50 2C to the SGCC gene
at 13q12 for g -sarcoglycan,51-53 2D to the SGCA gene
at 17q21 for a -sarcoglycan,54-56 2E to the SGCD gene
at 4q12 for b -sarcoglycan,57-59 2F to SGCD at 5q33
for d -sarcoglycan,60,61 2G to 17q11-12,62 and 2H to
9q31-33.63
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It is now understood that histopathologically de-
fined sarcoglycanopathy actually encompasses at least
four disease entities. The sarcoglycan complex con-
sists of five units—a -, b -, g -, d -, and e -sarcoglycans,
with muscular dystrophies being associated with the
first four. The integrity of the entire sarcoglycan com-
plex is interdependent on each of its components. If one
of the sarcoglycans represents the primary deficit, the
membrane staining for any of the others will also be
affected. Genetic testing is required to differentiate be-
tween the sarcoglycanopathies, although it is of limited
clinical relevance in the absence of specific therapies.
The pathogenesis of muscular dystrophies is still not
entirely known. Dystrophin and sarcoglycan are com-
ponents of the dystrophin-glycoprotein complex, which
is a membrane-associated muscle protein that spans the
muscle sarcolemma. The dystrophin-glycoprotein com-
plex is thought to have a key role in maintaining the sta-
bility of the muscle membrane. It is generally believed
that the disruption of the dystrophin-glycoprotein com-
plex would lead to a cascade of events that results in
muscle cell damage. Replacement of a normal variant
of mutant protein, either directly or by molecular
manipulation, is one of the strategies underlying gene
therapy.
For structural protein deficiencies, direct replace-
ment is unlikely to be successful. Trials of dystrophin
replacement in DMD by cell transfer using donor myo-
blasts have so far been disappointing.64-66 Molecular
manipulation includes somatic-cell gene replacement
therapy (SGRT) and ‘gene fixing’. Somatic-cell gene
replacement therapy works by inserting a functional
allele of the mutant gene into the cells of vulnerable
tissues. Experiments on SGRT have been undertaken
in animal models of DMD, and a , g , and d  sarcogly-
cannopathies. The general approach is to transfer the
dystrophin gene with a high capacity, non-pathogenic,
non-immunogenic vector via an acceptable route of
administration. Numerous technical obstacles, however,
remain to be overcome. Manipulation of DNA to cor-
rect defects—so called ‘gene fixing’—constitutes a
much greater challenge than SGRT. In DMD, gene fix-
ing could consist of transforming an out-of-frame into
an in-frame mutation by introducing an exon-skipping
RNA oligonucleotide so that a more stable protein can
be created. This would transform the DMD phenotype
into a more benign Becker-like phenotype.
Motor neuron disease
Five to ten percent of cases of motor neuron disease
(MND) are familial. The mode of inheritance is
autosomal dominant. In 15% to 20% of familial cases,
the disease is associated with mutations in the SOD-1
gene on chromosome 21.67 This gene encodes the
copper- and zinc-dependent superoxide dismutas
(SOD-1). Superoxide dismutase-1 converts the super-
oxide anion into hydrogen peroxide, which is then me-
tabolised into water and oxygen. Thus, SOD-1 plays
an essential role in free-radical scavenging. Most of
the mutations seen result in a variable loss of SOD-1
activity, but such a loss of activity is unlikely to be the
main mechanism underlying MND. The current think-
ing is that the mutated SOD-1 acquires a new cytotoxic
activity. Free radicals, including hydroxyl radicals
and nitronium ions, are paradoxically generated. The
reason for motor neuron selectivity remains unknown.
It is postulated that oxidative stress associated with
SOD-1 mutations renders motor neurons more vulner-
able to glutamate-induced excitotoxicity.
It is reasonable to assume that MND has multiple
aetiologies, which include the interaction of one or
more susceptibile genes, undetermined environmen-
tal factors, and physiological cell ageing. The under-
lying genetic defect is unknown in at least 98% of
cases.
Huntington’s disease
The genetic defect in Huntington’s disease (HD) was
found to be an unstable CAG repeat in the open read-
ing frame of the HD gene at 4p16.3,68 encoding
huntingtin, which is of unknown function. The result
of this defect is the expression of an elongated protein
that has polyglutamine residues. The exact pathogenic
mechanism of HD is not fully understood. Various hy-
potheses have been proposed, but none has yet been
proven in vivo. It is thought that the polyglutamine
expansion would contribute to a ‘gain of function’.
Intranuclear inclusions of huntingtin and ubiquitin are
found in affected neurons. One possible explanation
is that the mutant huntingtin conjugates with ubi-
quitin and is transported into the nucleus through an
aberrant proteasome complex. The resulting protein-
protein aggregates may accelerate apoptosis. A simi-
lar mechanism might also account for the neuronal
damage seen in other CAG repeat disorders, such as
some of the SCAs and DRPLA.
Presymptomatic HD can be diagnosed by genetic
analysis, but application of genetic testing remains
controversial. The test identifies a life-threatening
genetic defect that has no available remedy. As the
implications for individuals testing positive are im-
mense owing to the high penetrance of the genetic
HKMJ Vol 7 No 1 March 2001      45
Molecular biology and clinical neurology
defect, guidelines on presymptomatic screening should
be strictly observed.69
The adult-onset form of DRPLA, commonly with
choreoathetosis and psychiatric manifestations, is
often misdiagnosed as HD. Hence, all patients with an
HD-like illness but without the appropriate mutation
should be tested for DRPLA.
Alzheimer’s disease
Although approximately 30% of patients with Alz-
heimer’s disease (AD) have a positive family history,
most of them probably represent sporadic cases, be-
cause it is a very common condition with a prevalence
of almost 50% by the age of 85 years.70 The genetic
basis of early-onset AD differs from late-onset AD.
Approximately 50% of cases of early-onset AD involve
mutations of the presenilin 1 (PS1) gene at 14q24.3.71
Less common loci include that coding for the amyloid
precursor protein (APP) gene at 21q21.272 and the
presenilin 2 (PS2) gene at 1q31-q42,73 both of which
occur in less than 1% of cases. In late-onset AD, ap-
proximately 30% of cases involve a 2-macroglobulin
gene mutations at chromosome 12,74 and 40% are
associated with the apolipoprotein E (APOE) e 4 allele
at 19q13.2.75 Only a small proportion of late-onset
disease is associated with PS1, PS2, or APP mutations.
It is believed that early-onset AD is a heterogeneous
set of disorders caused by genetic mutations that are
unique to different families. In contrast, late-onset
AD is a sporadic disease influenced by multiple
environmental and genetic factors.
APOE- e 4 homozygous individuals have an eight-
fold increase in risk for developing AD, the onset
being on average 10 to 20 years earlier. Heterozygous
carriers have a three-fold increase in risk, and disease
onset is 5 to 10 years earlier. Conversely, the APOE-
e 2 allele may be protective against AD.76 b -Amyloid
(A b ) is an important component of senile plaques
and is thought to play a central role in the pathogenesis
of AD. The affinity for Ab  is different for the three vari-
ants of apolipoprotein E, with e 4 having the highest
affinity. The APOE- e 4 allele is associated with in-
creased deposition of fibrillar Ab , which is shown to
be neurotoxic in vitro and in vivo.77 The precise physio-
logical function of APPs and presenilins is not fully
understood. The mutated proteins result in altered
amyloidogenesis through an abnormal processing of APP.
This results in increased synthesis and accumulation of
Ab  peptides. The proteases b - and g -secretases may be
important mediators of this process. a 2-Macroglobulin
is a serum protease inhibitor. Its role in AD is also unclear.
The neurofibrillary tangles in AD are composed
predominantly of hyperphosphorylated tau. Mutations
of the tau gene on chromosome 17q21-22 are found in
frontotemporal dementia and parkinsonism.78 No tau
gene mutations, however, have been identified in AD.
The diagnosis of AD is based on clinical criteria
after the exclusion of other conditions that can cause
dementia.79 APOE- e 4 mutation is only a risk factor,
rather than mandatory, for the development of AD.
Genotypic determination has no role in the diagnosis
of AD, and no specific treatment that targets the
underlying disease process is yet available. Use of
anticholinesterases, such as tacrine and donepezil,
produces benefits in cognitive function but must be
viewed as palliative therapy. Genetic findings currently
seem to have little impact on patient management.
Recent experiments, however, might open up new
therapeutic options. Schenk et al80 showed that immu-
nisation with A b 42 in transgenic mice carrying the
mutant APP gene could prevent AD-associated patho-
logical changes, although a functional correlate was
not demonstrated. Whether non–APP-related models
can also benefit from this potential therapy is uncertain.
Other potential therapies include the use of specific
inhibitors of b - and g -secretases, and Ab  fibrillogenesis.
Parkinson’s disease
Results from twin studies initially did not appear to
support a genetic component to the aetiology of idio-
pathic Parkinson’s disease (PD).81,82 Familial parkin-
sonian syndromes broadly resemble idiopathic PD,
but unusual features are seen, such as early age of
onset, rapid progression, prominent dementia, or atypi-
cal pathology in some pedigrees. Molecular studies
of large families have been crucial in understanding
the pathogenesis of parkinsonism. Golbe et al83 have
linked the Contursi kindred to 4q21-23. Subsequent
studies have also linked these families to a rare muta-
tion in the a -synuclein gene,84 but most familial
parkinsonian syndromes and sporadic PD do not have
this mutation.85 Homozygous deletion of exons in the
Parkin gene have recently been detected in Japanese
families with autosomal recessive juvenile parkinson-
ism,86 an atypical parkinsonian syndrome characterised
by early onset, marked response to levodopa, and
susceptibility to levodopa-induced dyskinesia.
Paroxysmal disorders and channelopathies
Ion channels are membrane proteins that typically con-
sist of four to six subunits that are specifically adapted
for transmembrane ion flux regulation. The subunits
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are assembled to form channels that have different
degrees of permeability to various ions and different
opening and closing kinetics. Disorders of ion channels
commonly affect excitable tissues such as muscle
and nerve, thereby resulting in their paroxysmal
dysfunctions. The first channelopathy to be character-
ised genetically was hyperkalaemia periodic paralysis.
Electrophysiological studies in this disorder show
defective activation of the muscle membrane voltage-
gated sodium channels. The other two overlapping
conditions are paramyotonia congenita and potassium-
aggravated myotonia. These are of autosomal dominant
inheritance.
Hyperkalaemia periodic paralysis is characterised
by episodes of muscle weakness, which are triggered
by rest after a heavy workload, with myotonia between
attacks. Paramyotonia congenita manifests as a stiff-
ening of muscles during exercise or exposure to cold
that can develop into flaccid weakness that last sev-
eral hours. Potassium-aggravated myotonia is charac-
terised by exercise-induced myotonia with delayed
onset (approximately 20 minutes). It can be precipi-
tated by ingestion of potassium-rich food. The paraly-
sis can be relieved by administering thiazide diuretics
or acetazolamide, and the myotonia by class I antiar-
rhythmic drugs. Genetic studies have shown that these
diseases are linked to the SCN4A gene at 17q23,87,88
which codes for the a  subunit of skeletal muscle
sodium channels. In all these disorders, the underlying
pathogenic mechanism is essentially the same—
failure to maintain muscle membrane in the refractory
state due to a leaky channel. Other muscle voltage-
gated channelopathies include hypokalaemic periodic
paralysis, malignant hyperthermia, central core disease,
and myotonia congenita. The first three involve the cal-
cium channels and the last affects the chloride channel.
Neuronal voltage-gated channelopathies are poten-
tial candidates for common paroxysmal disorders such
as migraine and epilepsy. Some rare forms of these
conditions are now established to be genetic channel-
opathies. Familial hemiplegic migraine (FHM) is
associated with mutations of the CACNA1A gene at
19p13 which encodes for the a 1A-subunit of P/Q-type
voltage-gated calcium channel. Familial hemiplegic
migraine is characterised by migrainous headache,
which is preceded by an aura of hemiplegia that can
last for hours to days. CACNA1A gene mutations are
also found in SCA6 and episodic ataxia type 2 (EA2).
Episodic ataxia type 2 and FHM are overlapping syn-
dromes, with basilar migraine occurring in half of the
EA2 families and ataxia in 20% of FHM families.89 A
second locus for FHM has recently been mapped to
chromosome 1q at or near the R type voltage-gated
channel a 1E subunit gene.90,91 Generalised epilepsy
with febrile seizure plus presents with febrile seizures
beyond the age of 6 years, and non-febrile generalised
seizures until puberty. The SCN1B gene at 19q13.1,
which encodes the voltage-gated sodium channel
accessory b 1-subunit, is involved. Its disruption may
result in neuronal hyperexcitability—a mechanism
similar to that of myotonia. Benign familial neonatal
convulsions are associated with mutations in the
KCNQ2 gene at 20q1392 or the KCNQ3 gene at 8q,93
which encodes for voltage-sensitive neuronal potas-
sium channels. Autosomal dominant nocturnal frontal
lobe epilepsy is linked to 20q13.2 and the mutations
affect the a 4-subunit of the neuronal nicotinic acetyl-
choline receptor. 94, 95 Although the above conditions
account for no more than 1% of cases of migraine and
epilepsy, identification of their underlying disease mecha-
nisms suggests that genetic susceptibility might exist
for the more common paroxysmal disorders and that ion
channel dysfunction may have an important pathogenic
role.
Conclusion
The development of molecular biology has undoubt-
edly altered our understanding of the nervous system
and its disorders. Our knowledge of the pathophysiol-
ogy of neurological diseases is still relatively scant,
but increased insights in molecular biology will even-
tually translate into potential rational therapies for
neurological disorders, many of which are currently
incurable. The identification of molecular defects is
the first step in this direction. To date, advances in this
area have certainly helped in the reclassification of
some neurological disorders. Previous classifications,
especially of inherited neurological disorders, have
been based on clinical features, conventional labora-
tory methods and radiology, and they have been con-
founded by existing phenotypic heterogeneity. In
certain neurological disorders—for example, HD—
advances have translated into clinically viable diag-
nostic tests, which are useful in genetic counselling.
Until viable treatment options are developed for these
disorders, however, difficult ethical issues with such
techniques remain. Whether these developments will
lead to meaningful alterations in clinical management
currently remains unclear.
Apart from hereditary disorders, molecular biology
has undoubtedly assisted in exploring the pathogenic
mechanisms of many sporadic neurological disorders
including AD, PD, and MND. Although the develop-
ment of molecular techniques is rapidly increasing, it
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is by no means a panacea to the understanding and
eventual rational therapy of neurological disorders.
Development in other technologies such as cellular
biology and bioinformatics will certainly play an
integral role towards reaching this goal.
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